Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid ...

The use of stereotactic body radiotherapy (SBRT) as salvage therapy after radical prostatectomy was well tolerated, with no ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...

Risk for the autoimmune hair disorder was reduced by nearly 75% in patients on these treatments for psoriasis, finds a ...

The latest annual TIME100 Health list, which debuted in 2024, highlights scientists, doctors, advocates, educators, and other ...

Abbott India Dividend: In a big boost for its company shareholders, Abbott India announced a bumper final dividend of Rs 475 ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

Just before the May 5 trial date set for Novartis and Incyte to finally hash out their Jakafi royalty dispute in court, the ...

German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.

Basel, May 15, 2025 – Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical ...

After decades of hype and setbacks, scientists have made impressive progress into tricking stem cells into repairing organs.